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Prevalence and phenotype of diabetes and 
prediabetes using fasting glucose vs HbA1c  
in a Caribbean population
Background Both fasting plasma glucose (FPG) and HbA1c are rec­
ommended for the diagnosis of diabetes and prediabetes by the 
American Diabetes Association (ADA), and for diabetes by the World 
Health Organization. The ADA guidance is influential on clinical 
practice in many developing countries, including in the Caribbean 
and Latin America. We aimed to compare the prevalence and char­
acteristics of individuals identified as having diabetes and prediabe­
tes by FPG and HbA1c in a predominantly African ancestry Carib­
bean population.
Methods A representative population–based sample of 1234 adults 
(³25 years of age) resident in Barbados was recruited. Standard 
methods with appropriate quality control were used to collect data 
on height, weight, blood pressure, fasting lipids and history of diag­
nosed diabetes, and to measure fasting glucose and HbA1c. Those 
with previously diagnosed diabetes (n = 192) were excluded from 
the analyses. Diabetes was defined as: FPG ³7.0 mmol/L or HbA1c 
³6.5%; prediabetes as: FPG ³5.6 to <7mmol/L or HbA1c ³5.7 to 
<6.5%.
Results Complete data were available on 939 participants without 
previously diagnosed diabetes. The prevalence of undiagnosed dia­
betes was higher, but not significantly so, by HbA1c (4.9%, 95% CI 
3.5, 6.8) vs FPG (3.5%, 2.4, 5.1). Overall 79 individuals had diabe­
tes by either measure, but only 21 on both. The prevalence of pre­
diabetes was higher by HbA1c compared to FPG: 41.7% (37.9, 45.6) 
vs 15.0% (12.8, 17.5). Overall 558 individuals had prediabetes by 
either measure, but only 107 on both. HbA1c, but not FPG, was 
significantly higher in women than men; and FPG, but not HbA1c, 
was significantly associated with raised triglycerides and low HDL 
cholesterol.
Conclusion The agreement between FPG and HbA1c defined hy­
perglycaemia is poor. In addition, there are some differences in the 
phenotype of those identified, and HbA1c gives a much higher prev­
alence of prediabetes. The routine use of HbA1c for screening and 
diagnosis in this population would have major implications for clin­
ical and public health policies and resources. Given the lack of ro­
bust evidence, particularly for prediabetes, on whether intervention 
in the individuals identified would improve outcomes, this approach 
to screening and diagnosis cannot be currently recommended for 
this population.
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Globally there are estimated to be over 400 million people with diabetes, and of these 4 out of 5 live in 
low and middle income countries [1]. Diabetes is estimated to cause 5 million deaths per year, and is a 
major contributor to premature adult mortality [1]. A substantial proportion of people with Type 2 dia­
betes, which comprises approximately 90–95% of all persons with diabetes, are undiagnosed. This un­
diagnosed proportion can be as high as 80–90% in some of the poorest settings, such as in many of the 
countries of sub–Saharan Africa, and is typically around 20–30% in the world’s richest countries, includ­
ing most of those in Western Europe and North America [1].
In addition to individuals with diabetes, there are those with ‘prediabetes’ [2], also known as ‘intermedi­
ate hyperglycaemia’ [3]. These individuals have glucose levels that are above normal, but below the diag­
nostic threshold for diabetes. They are at increased risk of developing diabetes. There are three broad cat­
egories of prediabetes, and there is excellent evidence that among persons with one category (impaired 
glucose tolerance, which is based on the 2–hour post challenge result in an oral glucose tolerance test) 
the risk of developing diabetes can be substantially lowered through changes in diet and physical activ­
ity or the use of metformin [4].
There have been two major changes over the past 20 years to the diagnostic criteria for diabetes. In 1997 
the American Diabetes Association (ADA) lowered the diagnostic cut–point for fasting plasma glucose 
from 7.8 mmol/L to 7 mmol/L, and recommended that fasting glucose becomes the main diagnostic test, 
rather than the more time–consuming and expensive oral glucose tolerance test, which includes collec­
tion of a fasting sample and a sample 2 hours after a 75g glucose load [5]. In 2009, the International Ex­
pert Committee, which included the ADA, recommended that the diagnosis could also be made using 
glycated haemoglobin, HbA1c, at a cut–point of 6.5% [6]. HbA1c reflects the exposure of red cells to glu­
cose over their lifetime. In a person with normal haemoglobin the average lifespan of red cells is around 
120 days [7], with the average age of red cells in circulation being in the order of 40–60 days [8]. HbA1c 
therefore can be interpreted as reflecting average glucose levels over this time. The major advantage of 
HbA1c is that it does not require the person to be fasting, but it has the disadvantage of being more ex­
pensive to measure, and that the result can be influenced by medical conditions that affect red cell turn­
over and/or produce abnormal haemoglobin [9]. The World Health Organization (WHO) followed in 
lowering the cut–point for fasting glucose and in accepting HbA1c as a diagnostic test in 1999 [10] and 
2011 [9], respectively. However, unlike the ADA, WHO still emphasizes the desirability of continuing to 
use an oral glucose tolerance test as the gold standard for the diagnosis of diabetes, while acknowledging 
that the use of fasting glucose or HbA1c is more practical.
While the ADA and WHO diagnostic criteria for diabetes are identical, there are two major differences 
when it comes to the diagnosis of prediabetes (the ADA term) or intermediate hyperglycaemia (the WHO 
term). First, the ADA cut–point for prediabetes based on fasting plasma glucose (FPG) at 5.6 mmol/L [11] 
is lower than that recommended by WHO at 6.1 mmol/L [3]. Second, WHO does not believe that there is 
enough evidence to recommend using HbA1c to diagnose prediabetes [9], whereas the ADA does and de­
fines it as an HbA1c level from 5.7 to <6.5% [11]. It is relevant to the aims of the work present here to note 
that the ADA recommends that all people with prediabetes, whatever the method of diagnosis, are entered 
into a structured diabetes prevention programme [11]. Thus, if changing the approach to diagnosis chang­
es the numbers of individuals identified, this would have implications for health care resources.
The Caribbean is an ethnically and linguistically diverse region [12], that includes 18 English–speaking 
countries and territories that are part of the Caribbean Community (CARICOM) [13] and have some of 
the highest rates of diabetes and diabetes mortality in the Americas [1,14]. Barbados, where the work de­
scribed here was undertaken, is part of the English–speaking Caribbean and a member of CARICOM. It 
is an independent country, with a population of around 280 000, over 90% of whom are of African an­
cestry [15]. While the diagnosis of diabetes in Barbados and other parts of the Caribbean to date has 
largely relied on fasting glucose, ADA guidance [11] is highly respected and influential, and the greater 
availability of accessible and good quality HbA1c assays means that it is increasingly being used.
In this paper we make use of a recently conducted population–based survey [16] in which all participants 
had both FPG and HbA1c measured. Our aim was to assess what difference, if any, would using HbA1c 
rather than FPG make to the identification of diabetes and prediabetes. Specifically, we sought to deter­
mine whether there would be a difference in prevalence of the conditions, the individuals identified and 
the characteristics of those individuals. Our aim was not to determine which measure better predicts com­
plications or progression (that would require a very different type of study), but rather to determine what 
the local policy and resource implications might be of using one approach compared to the other. This, 
as far as we can determine, is the first study of its type conducted in the Caribbean.
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Prevalence and phenotype of diabetes and prediabetes in a Caribbean population
METHODS
Overview of the study design and data collection
The Health of the Nation survey was a cross–sectional study of the Barbadian population aged 25 years 
and older, which aimed to provide estimates of the prevalence and social distribution of non–communi­
cable diseases (NCDs) and their risk factors. Data were collected for 1234 participants on health condi­
tions and behaviours, as well as sociodemographic information. Data collection took place between Sep­
tember 2011 and May 2013. The survey methods have been described in detail elsewhere [16] and are 
summarised here.
On behalf of the Ministry of Health of the Government of Barbados, and in collaboration with the Barba­
dos Statistical Service, a multistage sampling process was used, with enumeration districts (EDs) selected 
with a probability proportional to their population size, households randomly selected within each ED, 
and a single eligible participant randomly selected from each household using the Kish method [17]. Staff 
from the Barbados Statistical Service made the first contact with each household and, if permission was 
given, the household details were passed on to members of the Health of the Nation survey team.
Data collection took place in participants’ homes across two visits. At the first visit a standard question­
naire was completed by interview. Items collected included whether the participant had been told by a 
doctor that they had diabetes, and if so what type of treatment they were on. At this first visit, height, 
weight, waist and hip circumferences were recorded, and blood pressure was measured using an Omron 
HEM–705CP digital machine. Standard protocols were followed for all measurements, and data collec­
tion staff were trained and accredited in their use.
At the end of this first visit a second early morning visit was arranged for the collection of a venous blood 
sample, typically on the day after the first visit. The participant was instructed to fast overnight for at least 
9 hours, drinking nothing other than water. The venous sample was collected into two tubes: a sodium 
fluoride tube and an EDTA tube. The sodium fluoride tube was placed immediately on wet ice, and the 
EDTA tube was placed in a cool box, which contained ice packs.
Assays of glucose, HbA1c and lipids
The sodium fluoride tube was kept on wet ice until its contents were analysed for plasma glucose later 
that morning. This analysis was undertaken at the Barbados Reference Laboratory using the glucose hexo­
kinase method on Roche Cobas 6000 (Roche Diagnostics, Mannheim, Germany).
The sample in the EDTA tube was used for HbA1c and lipid analyses. All analyses were conducted dur­
ing the same morning as the sample collection. Lipids (total cholesterol, HDL cholesterol and triglycer­
ides) were analysed using a Reflotron biochemical analyser (Roche Diagnostics, Mannheim, Germany). 
HbA1c was analysed using a DCA 2000 analyser (Siemens Health Care Diagnostics, Munich, Germany), 
a method certified by NGSP and directly traceable to the DCCT reference [18] and which is not affected 
by common haemoglobin variants such as HbC and HbS [19]. Manufacturers’ recommended quality con­
trol procedures for all biochemical assays were followed throughout.
The Reflotron and DCA 2000 analyser were used as they provide assay methods that are practical, afford­
able, widely used in surveys and known to be of good quality compared to laboratory standard methods 
[20–23]. However, we wished to be able to align the HbA1c and lipid results with those from the Barbados 
Reference Laboratory, an internationally accredited laboratory (with the College of American Patholo gists 
– CAP). This was achieved by analysing duplicate samples, 56 for HbA1c and 50 for lipids. For HbA1c, 
this was done at the time of venepuncture by collecting blood into two separate EDTA tubes, with one 
tube going to the reference laboratory, where HbA1c was measured using high performance liquid chro­
matography (HPLC). For the lipids, 50 plasma aliquots, which had been stored at minus 80°C, were as­
sayed in the reference laboratory for total, HDL and LDL cholesterol and triglycerides on a Roche Cobas 
6000 analyzer.
Details of the comparison between the values of HbA1c and the lipids assessed by the two different assay 
methods are given in the supplementary material. There were small but statistically significant differenc­
es between the results from the survey assay methods and those in the Barbados Reference Laboratory. As 
would be expected, there was inter–individual variation in the size of the differences. These are expressed 
as the standard deviation of the differences [24] and show that 95% of the differences for the lipids lay 
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within 0.2 and 0.7 mmol/L (Table S1 in Online Supplementary Document) of the mean, and for HbA1c 
within 1% (Table S1 in Online Supplementary Document). As described in the supplement, simple 
 linear regression equations were applied to the survey results to align them with reference laboratory 
 values.
Statistical analyses
Data were analysed using Stata statistical software (version 13, StataCorp, College Station, Texas). Weights 
were applied to account for the sampling design, non–response at the ED level, and to match the age and 
sex distribution of the Barbadian population according to the 2010 census [15]. As described elsewhere, 
compared with the official population, provided by the 2010 Barbados Population and Housing Census, 
the survey generally under–sampled young adults and oversampled the elderly, and more women than 
men took part. These discrepancies were addressed by the weighting scheme, full details of which are 
available on–line in the publication by Howitt et al [16].
Categories of hyperglycaemia were defined according to the criteria of the ADA [11] and the WHO [3,9]. 
Diabetes was defined, according to both ADA and WHO criteria, as FPG ³7.0 mmol/L or HbA1c ³6.5%. 
Prediabetes according to ADA criteria was defined as FPG ³5.6 to <7 mmol/L or HbA1c ³5.7 to <6.5%. Pre­
diabetes (impaired fasting glucose) according to WHO criteria was defined as FPG of ³6.1 to <7 mmol/L.
Those with previously diagnosed diabetes (n = 192) were excluded from the analyses in which the classifi­
cation and characteristics according to FPG and HbA1c values were compared. Agreement was investi­
gated in unweighted analyses in which categories based on FPG and HbA1c were cross–tabulated. Un­
weighted kappa statistics, using the Kappa command in Stata, were calculated.
The characteristics of individuals with ADA–defined hyperglycaemia were investigated as follows. First, 
differences (with 95% confidence intervals) in means and proportions between individuals with hyper­
glycaemia (ie, above the prediabetes cut–point) and normoglycaemia were examined. This was performed 
separately for the HbA1c and FPG defined categories. Age and sex were compared, plus anthropometric 
and biological variables commonly associated with hyperglycaemia [25]: body mass index, waist circum­
ference, systolic and diastolic blood pressure, HDL cholesterol and triglycerides. The association of nor­
mo/hyperglycaemia with hypertension, as a binary variable (yes/no), was also examined, in order to allow 
for the fact that some individuals may have normal blood pressure readings because they are on treat­
ment. Hypertension was defined as being on [or using prescribed] medication for hypertension and/or 
systolic blood pressure >140 mm Hg and/or diastolic blood pressure >90 mm Hg. Second, logistic regres­
sion was undertaken to identify which characteristics were independently associated with hyperglycae­
mia. A backward step selection process was used, starting with all the independent variables in the mod­
el and removing the least significantly associated variable at each step. This was halted when all variables 
in the model were associated with a P value of at least <0.05. All the analyses were undertaken using the 
survey module in Stata, in order to apply appropriate weights given the sampling design, non–response 
and age and sex distribution of the Barbados population (as described above). Model specification was 
evaluated using the link test and goodness of fit using the ‘estat gof’ command [26].
Ethical considerations
Written informed consent was obtained from all participants. The study was approved by the Research 
Ethics Committee of the University of the West Indies, Cave Hill and the Barbados Ministry of Health. All 
persons in the study found to have abnormal results, including abnormal HbA1c or FPG, were informed 
and advised to seek medical advice and further investigation as needed.
RESULTS
There was a total of 1234 respondents (470 men and 764 women). Out of 2277 eligible households con­
tacted by the Barbados Statistical Service, 1646 (72.3%) agreed to having their details passed on to the 
Health of the Nation survey; from these, 1234 (75.0%) individuals participated in the study (see Howitt 
et al. for full details [16]).
Diagnosed diabetes was reported by 192 participants, 11.4% (95% confidence interval (CI) 8.3, 15.5) of 
men and 15.8% (95% CI 13.1, 18.8) of women (Table 1). Of the 1042 without a previous diagnosis of 
diabetes, complete data on fasting glucose and HbA1c were available on 939 (90%). In these individuals, 
the prevalence of previously undiagnosed diabetes ranges from 3.5% (95% CI 2.4, 5.1) (FPG criterion in 
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men and women) to 7.3% (95% CI 5.0, 10.4) (FPG and/or HbA1c criterion in men and women). The 
prevalence of previously undiagnosed diabetes is higher by the HbA1c criterion compared to the FPG in 
both women and men; and higher in women compared to men by both the HbA1c and FPG criteria. 
However, the confidence intervals are wide and overlapping.
The prevalence of prediabetes differs markedly by the three different sets of criteria (Table 1). The low­
est prevalence is for the WHO FPG criterion, with an overall prevalence in men and women of 4.9% (95% 
CI 3.5, 6.9). Applying the ADA FPG criterion triples the prevalence, to 15.0% (95% CI 12.8, 17.5). Ap­
plying the ADA HbA1c criterion gives more than double the ADA FPG prevalence, at 41.7% (95% CI 
37.9, 45.6). Defining prediabetes based on either FPG or HbA1c gives a prevalence of 44.1% (95% CI 
40.5, 47.9).
The agreement between diabetes and prediabetes according to ADA FPG vs HbA1c criteria is poor, re­
flected by low kappa values (Table 2). For example, there are 43 individuals with previously undiagnosed 
diabetes based on FPG, and 57 based on HbA1c, but only 21 on both (kappa 0.39, 95% CI 0.32, 0.45). 
With prediabetes there are 170 based on FPG, 495 on the HbA1c, and only 107 on both (kappa 0.14, 
95% CI 0.10, 0.19).
Anthropometric and biological characteristics 
of those without a previous diagnosis of diabe­
tes are summarised in Table 3. There are no­
table differences between men and women, 
with women having a significantly (based on 
the lack of overlap between 95% confidence 
intervals) higher body mass index, HbA1c, to­
tal and HDL cholesterol, but similar fasting glu­
cose, and lower triglycerides and lower mean 
systolic blood pressure. A higher proportion of 
women than men are on treatment for hyperten­
sion. The prevalence of obesity (BMI ≥30 kg/m2) 
is 43.5% (95% CI 39.1, 48.0) in women and 
23.2% (95% CI 18.4, 28.8) in men.
Selected characteristics of those with ADA–de­
fined hyperglycaemia compared to those with 
normoglycaemia by FPG and HbA1c criteria 
are shown in Table 4. Older age, higher body 
mass index, waist circumference and blood 
Table 1. Prevalence of categories of diabetes and prediabetes in Barbadian adults (25 years and over)*
Men (n = 430) WoMen (n = 701) All (n = 1131)
Diagnosed diabetes (n = 192):
On hypoglycaemic medication 9.2 (6.6, 12.8) 13.8 (11.4, 16.7) 11.7 (9.8, 13.8)
Not on medication 2.1 (1.1, 4.1) 1.9 (1.0, 3.7) 2.0 (1.2, 3.3)
All 11.4 (8.3, 15.5) 15.8 (13.1, 18.8) 13.8 (11.7, 16.2)
Undiagnosed diabetes:†
FPG ³7.0 mmol/L 3.3 (2.0, 5.5) 3.7 (2.2, 6.3) 3.5 (2.4, 5.1)
HBA1c ³6.5% 3.9 (2.3, 6.5) 5.7 (3.9, 8.3) 4.9 (3.5, 6.8)
On either of above 5.7 (3.9, 8.3) 7.3 (5.0, 10.4) 6.5 (4.9, 8.6)
Prediabetes (WHO criteria):
FPG ³6.1 to <7 mmol/L 5.5 (3.5, 8.5) 4.4 (2.8, 6.7) 4.9 (3.5,6.9)
Prediabetes (ADA criteria):†
FPG ³5.6 to <7 mmol/L 16.7 (12.9, 21.2) 13.6 (10.6, 17.2) 15.0 (12.8, 17.5)
HBA1c ³5.7 to <6.5% 39.7 (33.8, 46.0) 43.4 (39.8, 47.2) 41.7 (37.9, 45.6)
On either of above 42.2 (35.9, 48.8) 45.8 (42.2, 49.4) 44.1 (40.5, 47.9)
FPG – fasting plasma glucose, HBA1c – haemoglobin A1c, ADA – American Diabetes Association
*Figures are percentages (95% confidence intervals), and are weighted for sampling design, non–response and the 
age structure of the Barbados adult population.
†See Table 2 for numbers of individuals (unweighted) by category.
Table 2. Agreement between categories of diabetes and prediabetes based on 
fasting plasma glucose (FPG) and HbA1c criteria*
FPG
HbA1c: Not diabetes Diabetes Total
Not diabetes 860 22 882
Diabetes 36 21 57
Total 896 43 939
Kappa (95% CI) 0.39 (0.32, 0.45)
ADA Categories based on FPG
ADA categories based on HbA1c Normal Prediabetes Diabetes Total
Normal 342 37 8 387
Prediabetes 374 107 14 495
Diabetes 10 26 21 57
Total 726 170 43 939
Kappa (95% CI) 0.14 (0.10, 0.19)
CI – confidence interval, FPG – fasting plasma glucose, HBA1c – haemoglobin A1c, ADA 
– American Diabetes Association
*Figures are numbers of study participants, and kappa statistics (95% confidence inter­
vals).
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Table 3. Characteristics of those without previously diagnosed diabetes, and with complete fasting glucose and 
HbA1c data*
Men WoMen All
Age in years (n, column %):
25–44 139 (38.5) 252 (43.6) 391 (41.6)
45–64 155 (42.9) 237 (41.0) 392 (41.8)
65+ 67 (18.6) 89 (15.4) 156 (16.6)
All 361 (100.0) 578 (100.0) 939 (100.0)
Glucose & HbA1c:
Mean fasting glucose (mmol/L) 5.2 (5.1, 5.3) 5.2 (5.1, 5.4) 5.2 (5.2, 5.3)
Mean HbA1c (%) 5.7 (5.6, 5.7) 5.8 (5.7, 5.9) 5.7 (5.7, 5.8)
Other:
Anthropometry
Mean BMI (kg/m2) 26.4 (25.7, 27.1) 29.8 (29.1, 30.5) 28.2 (27.8, 28.6)
Mean waist circumference (cm) 90.1 (88.1, 92.0) 92.6 (91.2, 94.1) 92.1 (91.1, 93.1)
Blood pressure:
Mean sBP (mmHg) 131.0 (129.1, 133.0) 126.5 (124.5, 128.6) 128.7 (127.3, 130.1)
Mean dBP (mmHg) 77.8 (76.3, 79.3) 76.8 (75.7, 77.8) 77.3 (76.4, 78.2)
% On treatment for hypertension 14.1 (10.9, 18.1) 25.3 (20.4, 30.8) 19.9 (16.7, 23.6)
Lipids:
Mean total cholesterol (mmol/L) 4.6 (4.5, 4.7) 4.9 (4.8, 4.9) 4.7 (4.7, 4.8)
Mean HDL cholesterol(mmol/L) 1.28 (1.25, 1.31) 1.40 (1.38, 1.43) 1.34 (1.32, 1.36)
Mean triglycerides (mmol/L) 0.96 (0.92, 1.00) 0.88 (0.85, 0.92) 0.92 (0.90, 0.94)
HBA1c – haemoglobin A1c, BMI – body mass index, sBP – systolic blood pressure, dBP – diastolic blood pressure, HDL – high 
density lipoprotein
*103 individuals of the 1042 without previously diagnosed diabetes had missing fasting glucose and/or HbA1c values. All figures, 
with the exception of the numbers by age group, are weighted for the sampling design, non–response, and the age structure of the 
Barbados adult population.
Table 4. Comparison of selected characteristics between groups with normal and raised fasting glucose or HbA1c 
based on ADA criteria*
norMAl rAised Absolute difference (95% ci)
Fasting glucose:
Age (years) 45.2 (0.8) 53.7 (1.5) 8.5 (5.5, 11.4)
Female sex (%) 52.7% 50.1% –2.8 (–12.3, 6.7)
BMI (kg/m2) 27.5 (0.4) 30.1 (0.6) 2.5 (1.0, 4.0)
Waist (cm) 89.8 (0.8) 97.0 (1.2) 7.0 (3.9, 10.2)
sBP (mmHg) 126.6 (0.7) 135.9 (1.9) 9.2 (5.3, 13.0)
dBP (mmHg) 76.4 (0.5) 80.3 (1.1) 4.1 (1.8, 6.3)
Hypertension (%)† 28.4 56.8 28.3 (19.0, 37.6)
HDL cholesterol (mmol/L) 1.36 (0.01) 1.29 (0.02) –0.07 (–0.12, –0.02)
Triglycerides (mmol/L) 0.97 (0.02) 1.17 (0.06) 0.20 (0.07, 0.34)
HbA1c:
Age (years) 41.3 (0.8) 51.9 (0.9) 10.9 (8.6, 13.2)
Female sex (%) 46.8% 56.6% 9.6 (2.5, 16.6)
BMI (kg/m2) 26.5 (0.4) 29.5 (0.4) 3.0 (1.7, 4.2)
Waist (cm) 87.0 (1.0) 94.9 (0.8) 7.7 (4.9, 10.5)
sBP (mmHg) 124.8 (1.0) 131.8 (0.9) 7.4 (4.8, 10.1)
dBP (mmHg) 75.9 (0.8) 78.4 (0.6) 2.8 (1.0, 4.7)
Hypertension (%)† 22.2 44.9 22.7 (15.3, 30.0)
HDL cholesterol (mmol/L) 1.34 (0.02) 1.34 (0.02) 0.00 (–0.05, 00.1)
Triglycerides (mmol/L) 0.96 (0.03) 1.05 (0.03) 0.09 (0.00, 00.2)
HBA1c – haemoglobin A1c, BMI – body mass index, sBP – systolic blood pressure, dBP – diastolic blood pressure, HDL – high 
density lipoprotein
*Figures are means (standard error) unless otherwise indicated.
†On BP lowering medication and/or blood pressure ³140/90. See text for details.
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pressure are all related to both FPG and HbA1c categories of 
hyperglycaemia. Higher triglyceride, and lower HDL choles­
terol levels are associated with FPG, but not HbA1c, defined 
hyperglycaemia. Female sex is associated with HbA1c, but not 
FPG, defined hyperglycaemia.
Backward step logistic regression, as described in the methods 
section and starting with all the variables shown in Table 4 was 
undertaken to identify factors independently associated with 
FPG and HbA1c categories of hyperglycaemia. The FPG cate­
gory was independently associated with age, waist circumfer­
ence, hypertension and triglycerides (Table 5). The HbA1c cat­
egory was associated with age, waist circumference and female 
sex, but not blood pressure, HDL cholesterol or triglycerides. 
In further analysis, waist circumference was entered into the mo­
del for HbA1c as a binary variable using sex specific cut–points 
(94 cm for women, 102 cm for men [27]). As shown in Table 5, 
this had the effect of reducing the association with female sex 
(odds ratio (OR) 1.25, 95% CI 0.94, 1.66).
DISCUSSION
In the first study of its type in the Caribbean, we compared the prevalence and agreement of diabetes and 
prediabetes as defined by FPG and HbA1c. We found that HbA1c gave a higher prevalence of both dia­
betes (non–significant) and prediabetes. Applying the ADA criteria, the prevalence of prediabetes was 
more than twice as high based on HbA1c compared to fasting glucose. The agreement between the two 
methods of classification was poor. There were also differences in the factors associated with HbA1c and 
FPG­defined hyperglycaemia. HbA1c, but not FPG, defined hyperglycaemia was associated with female 
sex. Raised FPG, but not HbA1c, defined hyperglycaemia was associated with raised triglycerides and 
hypertension. At a population level, therefore, there are important differences in terms of prevalence and 
the characteristics of the individuals identified.
While both HbA1c and FPG are recommended by the ADA and WHO for the diagnosis of diabetes, and 
by the ADA for the diagnosis of prediabetes, it is unclear whether one should be preferred over the other. 
Analyses of cross–sectional data from nine studies across five countries found that both FPG and HbA1c 
at the currently recommended diagnostic cut–points for diabetes were strongly associated with an in­
creased risk of diabetic retinopathy, whereas the 2–hour glucose from an oral glucose tolerance test was 
not [28]. Prediabetes, whether defined by HbA1c or FPG, is associated with an increased risk of develop­
ing diabetes [29]. However, it does not appear that one test is better than the other at predicting harder 
adverse outcomes, such as death or incident cardiovascular disease. For example, neither adds much to 
the prediction of cardiovascular events when other established cardiovascular risk factors are taken into 
account [30].
It is also unclear, given the currently available evidence, whether the lifestyle and pharmacological inter­
ventions that have been shown to substantially reduce the incidence of diabetes in those with impaired 
glucose tolerance [4], which requires an oral glucose tolerance test for diagnosis, are also effective in those 
with prediabetes based on FPG or HbA1c. It seems a reasonable assumption that they would be, and in­
deed guidance is based on this assumption [11]. However, hard evidence is lacking, and what does exist 
suggests that in the case of impaired fasting glucose these interventions may be either ineffective or much 
less effective [31,32]. Comparable studies targeting prediabetes based on HbA1c do not exist [29].
Other studies have also investigated differences in the prevalence of diabetes and prediabetes by different 
measures of glycaemia, whether HbA1c, FPG, or the use of an oral glucose tolerance test. A pooled anal­
ysis to investigate the impact on diabetes prevalence, based on 63 health examination surveys, found dif­
ferences in prevalence (both higher and lower), with similar prevalences in only a minority (15%) [33]. 
Differences in agreement between studies were significantly, but weakly, related to population differences 
in body mass index and gross domestic product [33]. For example, in a pooled regression analysis, the 
prevalence of diabetes by HbA1c, while controlling for the prevalence by FPG, was positively related with 
age, mean body mass index, and gross domestic project [33].
Table 5. Results of logistic regression to identify independent 
associations between hyperglycaemia and the characteristics 
in Table 4
odds rAtio 95% cis
Fasting glucose:
Age (years) 1.03 1.01, 1.04
Waist (cm) 1.03 1.01, 1.05
Hypertension (Y/N) 2.03 1.25, 3.30
Triglycerides (mmol/L) 1.46 1.07, 2.00
HbA1c:
Age (years) 1.05 1.04, 1.07
Female sex 1.40 1.03, 1.91
Waist (cm) 1.04 1.02, 1.06
HbA1c (model with sex specific “high waist”*):
Age (years) 1.06 1.04, 1.07
Female sex 1.25 0.94, 1.66
High waist (Y/N) 2.32 1.50, 3.58
HBA1c – haemoglobin A1c
*³94 cm in women; ³102 cm in men.
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Studies reporting differences in the prevalence of prediabetes by FPG and HbA1c have also found differ­
ences in both directions. In the Canadian Health Measures Survey, for example, differences in the preva­
lence of prediabetes in adults based on ADA criteria by FPG and HbA1c are similar to what we describe 
here: 13% using FPG vs 33% with HbA1c [34]. In the United States (US) NHANES study, by contrast, 
the prevalences of prediabetes were almost the reverse: 28.7% with FPG and 12.4% with HbA1c [35]. 
The reasons for these differences are not clear based on the published data. Neither study presented a 
comparison by sex, nor compared the characteristics of those with differently defined prediabetes. The 
higher prevalence of obesity in the US (30–33%) compared to Canada (20–22%) [36] is not obviously 
related to these differences. Interestingly, in a relatively small study (n = 216) of predominantly male (mean 
age 37 years) African migrants to the US, the prevalence of hyperglycaemia (taking the figures from Table 
2 in the paper) [37] using ADA criteria was 13% by FPG and 35% by HbA1c, similar to what we report 
in our study here.
It is also relevant to our findings to note that some analyses, in particular based on data from the US 
NHANES study, have described higher levels of HbA1c in black compared to white participants (‘black’ 
and ‘white’ being the terms used in the paper) independent of differences in fasting and post challenge 
glucose [38]. Similarly, in the Atherosclerosis Risk in Communities Study, HbA1c levels were higher in 
black compared to white participants independent of fasting glucose level [39]. The American Diabetes 
Prevention Program (conducted in adults with impaired glucose tolerance) also reported differences by 
ethnicity in average HbA1c levels, with higher levels in black compared to white participants, and these 
were independent of differences in obesity, fasting and post challenge glucose, and insulin resistance [40]. 
It may be, therefore, that relationships between measures of glucose (including fasting and post challenge) 
and HbA1c differ by ethnic group, with a higher HbA1c level in people of black African origin compared 
to people of white European origin [41,42]. The reasons for such differences remain unclear and include 
potential racial/ethnic differences in susceptibility to glycation of haemoglobin [41,42], and underlying 
average glucose concentrations being higher in African descent populations (and not properly accounted 
for by adjusting for fasting and post challenge glucose).
One little mentioned but possible contributory factor to population differences in HbA1c levels is iron 
deficiency. This may increase red cell life and thus HbA1c levels [43,44]. It is possible that iron deficien­
cy anaemia in women of child–bearing age contributes to the higher HbA1c levels in women found in 
our study. Unfortunately, haemoglobin was not measured in the survey, but WHO estimates for the prev­
alence of iron deficiency anaemia in Barbados suggest that around one in five to one in four women aged 
15–49 are anaemic [45]. The potential effect of iron deficiency anaemia on HbA1c levels requires further 
evaluation. Another, possibly more important, contributory factor to higher HbA1c levels in women com­
pared to men in Barbados is the higher prevalence of obesity, particularly abdominal obesity. Controlling 
for abdominal obesity, defined using sex–specific cut–points, reduced to non–significant the association 
of HbA1c defined hyperglycaemia with female sex.
Before drawing conclusions on the implications of the findings reported here, we should acknowledge 
both the strengths and limitations of the study. A strength is that this is a representative population–based 
study. Standardised methods were used to collect all data, most importantly to measure FPG and HbA1c. 
The method of HbA1c measurement used is approved by the NGSP [18] and widely used, and in addi­
tion we aligned these values to those from the only reference laboratory in Barbados that uses the gold 
standard approach of HPLC. Limitations of the study include that it was a relatively small study popula­
tion, and thus lacks precision to properly investigate some areas of interest, including differences in 
 diabetes prevalence by FPG or HbA1c. In addition, it was an epidemiological study using epidemiologi­
cal definitions of prediabetes and undiagnosed diabetes; ie, our definitions are based on a single measure­
ment, whereas in clinical practice, and in the absence of clear symptoms, a confirmatory diagnostic test 
should always be performed [3,11]. Finally, it is worth noting that the kappa statistic to assess agreement 
between categories based on FPG and HbA1c requires careful interpretation. Kappa values are influenced 
by the prevalence of the different categories, and when the prevalence is very different (such as the prev­
alence of diabetes vs no diabetes), Kappa may provide an overly negative summary of the agreement [46]. 
We recommend therefore that the Kappa values are only used and interpreted alongside the actual cross–
tabulated data (Table 2). Despite these limitations, our findings demonstrate marked differences between 
FPG and HbA1c in the identification of hyperglycaemia in the adult population of Barbados.
In conclusion, current guidance recommends the use of both FPG and HbA1c for the diagnosis of diabe­
tes and prediabetes. This study has shown that according to ADA guidance around 44% of the adult pop­
ulation of Barbados has prediabetes, with a further 6.5% having previously undiagnosed diabetes. When 
December 2017  •  Vol. 7 No. 2 •  020407 8 www.jogh.org •  doi: 10.7189/jogh.07.020407
Unwin et al.
V
IE
W
PO
IN
TS
PA
PE
RS
previously diagnosed diabetes is added, roughly two out of three (64%) adults are classified as having ei­
ther diabetes or prediabetes and thus the majority of the adult population would be recommended for 
clinical intervention [11]. By contrast, if WHO diagnostic guidance is followed then roughly one in four 
adults (25%) has either diabetes or prediabetes. In very well–resourced settings it might be considered 
prudent to measure both FPG and HbA1c and manage individuals accordingly, as is recommended [11]. 
However, in less well–resourced settings, such as in Barbados and most of the Caribbean, our findings 
indicate that the increasing use of HbA1c to diagnose diabetes and prediabetes could have major impli­
cations: for human and financial resources; clinical practice and public health policies; and for health 
systems that are already struggling to cope with the high and increasing burden of chronic diseases. In 
addition, there is limited evidence to support whether one approach is better than the other for identify­
ing individuals who will benefit from treatment. In short, the currently available guidance is particularly 
unhelpful, and potentially damaging (if it leads to less effective use of scarce resources), for situations in 
which resources are limited. We propose therefore that a pragmatic approach, guided by the currently 
available evidence, is to use FPG as the diagnostic test for both diabetes and prediabetes and to restrict 
the label of ‘prediabetes’ to the narrow range recommended by WHO. Expansion of the prediabetes cat­
egory, whether by adopting the broader ADA FPG range or using HbA1c criteria, should be contingent 
upon clear evidence that cost–effective interventions to improve outcomes are available [29].
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